These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 29457671)
1. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Brezing CA; Choi CJ; Pavlicova M; Brooks D; Mahony AL; Mariani JJ; Levin FR Am J Addict; 2018 Mar; 27(2):101-107. PubMed ID: 29457671 [TBL] [Abstract][Full Text] [Related]
2. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160 [TBL] [Abstract][Full Text] [Related]
3. Gender differences in health-related quality of life among cannabis users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Lev-Ran S; Imtiaz S; Taylor BJ; Shield KD; Rehm J; Le Foll B Drug Alcohol Depend; 2012 Jun; 123(1-3):190-200. PubMed ID: 22143039 [TBL] [Abstract][Full Text] [Related]
4. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969 [TBL] [Abstract][Full Text] [Related]
5. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users. Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387 [TBL] [Abstract][Full Text] [Related]
6. Quality of life and recreational cannabis use. Goldenberg M; IsHak WW; Danovitch I Am J Addict; 2017 Jan; 26(1):8-25. PubMed ID: 28000973 [TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823 [TBL] [Abstract][Full Text] [Related]
8. Non-abstinent treatment outcomes for cannabis use disorder. Levin FR; Mariani JJ; Choi CJ; Basaraba C; Brooks DJ; Brezing CA; Pavlicova M Drug Alcohol Depend; 2021 Aug; 225():108765. PubMed ID: 34087745 [TBL] [Abstract][Full Text] [Related]
9. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Schlienz NJ; Lee DC; Stitzer ML; Vandrey R Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485 [TBL] [Abstract][Full Text] [Related]
10. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551 [TBL] [Abstract][Full Text] [Related]
11. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol. Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233 [TBL] [Abstract][Full Text] [Related]
12. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917 [TBL] [Abstract][Full Text] [Related]
13. Quetiapine treatment for cannabis use disorder. Mariani JJ; Pavlicova M; Jean Choi C; Basaraba C; Carpenter KM; Mahony AL; Brooks DJ; Bisaga A; Naqvi N; Nunes EV; Levin FR Drug Alcohol Depend; 2021 Jan; 218():108366. PubMed ID: 33153828 [TBL] [Abstract][Full Text] [Related]
14. Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety. Laprevote V; Schwan R; Schwitzer T; Rolland B; Thome J Curr Pharm Des; 2015; 21(23):3298-305. PubMed ID: 26088109 [TBL] [Abstract][Full Text] [Related]
15. Open-label pilot study of injectable naltrexone for cannabis dependence. Notzon DP; Kelly MA; Choi CJ; Pavlicova M; Mahony AL; Brooks DJ; Mariani JJ; Levin FR Am J Drug Alcohol Abuse; 2018; 44(6):619-627. PubMed ID: 29420073 [TBL] [Abstract][Full Text] [Related]
16. Contingency management is associated with positive changes in attitudes and reductions in cannabis use even after discontinuation of incentives among non-treatment seeking youth. Cooke ME; Knoll SJ; Streck JM; Potter K; Lamberth E; Rychik N; Gilman JM; Evins AE; Schuster RM Drug Alcohol Depend; 2024 Mar; 256():111096. PubMed ID: 38277735 [TBL] [Abstract][Full Text] [Related]
17. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Sherman BJ; Sofis MJ; Borodovsky JT; Gray KM; McRae-Clark AL; Budney AJ Psychol Addict Behav; 2022 Aug; 36(5):505-514. PubMed ID: 34197135 [TBL] [Abstract][Full Text] [Related]
18. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. Notzon DP; Mariani JJ; Pavlicova M; Glass A; Mahony AL; Brooks DJ; Grabowski J; Levin FR Am J Addict; 2016 Dec; 25(8):666-672. PubMed ID: 28051838 [TBL] [Abstract][Full Text] [Related]
19. Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Sherman BJ; Baker NL; McRae-Clark AL Addict Behav; 2016 Sep; 60():197-202. PubMed ID: 27156221 [TBL] [Abstract][Full Text] [Related]